Frontier mental health research: psychedelics & drug studies

Key findings

• Ayahuasca is a traditional Amazonian brew made from the Banisteriopsis caapi vine plus a DMT-containing plant so the DMT works when you drink it. ^{15090 15082}
• Researchers are studying ayahuasca for conditions such as major depression (including treatment-resistant depression), anxiety, post-traumatic stress, and addiction. ^{15082 15060 15059 15068}
• In clinical research, ayahuasca is usually given by mouth in supervised sessions that include preparation before and therapy after the drug session. ^{15063 15082 15090}
• Small trials and clinical reports show short-term improvements in mood and well-being after ayahuasca or DMT, with the strongest and most consistent promise so far for certain forms of depression. ^{15082 15060 15090}
• Ayahuasca’s active chemical (DMT) mainly affects serotonin-related brain receptors and lab studies suggest it can change brain networks and promote neuroplasticity (the brain making new connections). ^{15046 15050 15091 15082}
• There are safety concerns: reports exist of physical and psychological harms after ayahuasca, and one large naturalistic study found higher psychotic or manic symptoms after psychedelic use when the use occurred in illegal or uncontrolled settings. ^{15090 15133 15046}
• Research so far is limited: many trials are small, the field needs larger and longer studies, and people of color have been underrepresented so results may not apply to all groups. ^{15064 15085 15095 15082}
• Some lab and animal studies show DMT can increase synapse growth, but human studies measuring a brain-growth blood marker (BDNF) after psychedelic drugs have not shown clear changes, so biological mechanisms remain uncertain. ^{15050 15129}